Absence of Glucocorticoids Concomitant With Avacopan and Subsequent Liver Injury in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Abstract

Avacopan, a C5a receptor (C5aR) inhibitor, has emerged as a novel treatment for antineutrophil cytoplasmic antibody–associated vasculitis (AAV), providing an alternative to glucocorticoids (GCs).¹ Despite its promising potential, severe liver dysfunction associated with avacopan has been reported in Japan.^2,3